BMY Q4 2025 earnings call recap: growth portfolio momentum, pipeline catalysts, 2026 guidance, and Eliquis LOE risks.

Bristol Myers Squibb is leaning heavily on its newer key products, grouped into its growth portfolio category, to weather the storm it expects as it heads toward further declines within its legacy | ...

The researchers note that circadian rhythms - the 24-hour cycles governing biological processes - are known to influence ...

Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body's natural rhythms ...

A new study highlights the critical role of advanced AI-integrated battery management system technologies in monitoring, optimizing, and predicting battery performance for reliable and sustainable ...

Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced ...

Artemis II echoes the Apollo-era missions that paved the way for the first moon landing — and sets the stage for what comes ...

Experts explore 3-year clinical data on bimekizumab presented at the 2025 EADV and SHSA congresses, highlighting its durable and ...

While many people are growing deeply concerned about the negative impact artificial intelligence might have on our fragile ...

Ascension, Tenet and HCA Healthcare may be some of the biggest names in health system ASC strategy, but they’re not the only ones betting on outpatient growth. Across the country, more hospitals and ...